MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA. The ‘rolling ...

Orchestrate end-to-end encryption, cryptographic identities, mutual authentication, and authorization policies between distributed applications – at massive scale.

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

The Indicator from Planet Money A little show about big ideas. From the people who make Planet Money, The Indicator helps you make sense of what's happening today. It's a quick hit of insight into ...